semaglutide cvot trial In patients with type 2 diabetes and atherosclerotic cardiovascular disease, tirzepatide was noninferior to dulaglutide with respect to major cardiovascular events. ⁣, ⁣, Read the full SURPASS-CVOT fig1.jpg

Those numbers will appear in the full scientific presentation

(2022) [59] comparing GLP-1RA plus SGLT2i combination therapy to GLP-1RA and SGLT2i monotherapies among 1,895 patients with T2DM enrolled in 8 RCTs, the addition of a GLP-1RA to SGLT2i treatment showed that drug discontinuation, diarrhea, injection-site-related events, nausea, vomiting and genital infections were more likely to occur in combination therapy

Furthermore, clinical data shows patients who stop taking Semaglutide regain 2/3 of their weight within a year

You use nasal tanning spray

A healthy follicle can keep this up for 2 to 7 years , but throw in poor nutrition or a hormonal curveball, and it might clock out early